Myocardial infarction treated with two lymphagogues, calcium dobesilate (CLS 2210) and hyaluronidase

A coded, placebo-controlled animal study

I. Repa, J. Daniel Garnic, Norman K. Hollenberg

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The effects on the evolution of canine myocardial infarction (MI) of the lymphagogues hyaluronidase (hyaluronate glucanohydrolase) (known to reduce the size of MIs) and calcium dobesilate (calcium, 2,5-dihydroxybenzenesulfonate, CLS 2210) were compared in a coded, placebo-controlled study in 48 dogs, during the first 24 h after coronary occlusion. Ml was induced by embolization of the anterior descending branch of the left coronary artery. The animals were given either a placebo, CLS 2210, or hyaluronidase by intravenous infusion begun immediately after embolization and continued for 24 h. The volume of myocardial tissue at risk was evaluated at 2 and 24 h by ungated computed tomography (CT), and after necropsy by staining myocardial sections with triphenyl tetrazolium chloride (TTC). Electrocardiography and estimation of serum creatine kinase (CK.) activity were also performed. In the 25 animals that survived 24 h, the results of all tests showed that there was less myocardial damage in the animals treated with the two lymphagogues than in those treated with placebo, and less damage with CLS 2210 than with hyaluronidase. The good correlation between the volume of ischemic tissue as assessed by CT in vivo and as assessed by TTC staining after necropsy (r = 0.959) confirms that the CT per-fusion phase defect accurately reflects the volume of tissue at risk during the evolution of MI. This study has shown that CLS 2210 is at least as effective as hyaluronidase in reducing myocardial damage due to coronary artery occlusion in dogs.

Original languageEnglish
Pages (from-to)286-291
Number of pages6
JournalJournal of Cardiovascular Pharmacology
Volume16
Issue number2
Publication statusPublished - 1990

Fingerprint

Calcium Dobesilate
Hyaluronoglucosaminidase
Myocardial Infarction
Placebos
Coronary Occlusion
Tomography
Chlorides
Coronary Vessels
Dogs
Staining and Labeling
Creatine Kinase
Intravenous Infusions
Canidae
Electrocardiography
Calcium
CLS 2210
Serum

Keywords

  • Calcium dobesilate (CLS 2210)
  • Computed tomography
  • Creatine kinase
  • Electrocardiography
  • Hyaluronidase
  • Myocardial infarction
  • Triphenyl tetrazolium chloride

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Myocardial infarction treated with two lymphagogues, calcium dobesilate (CLS 2210) and hyaluronidase : A coded, placebo-controlled animal study. / Repa, I.; Daniel Garnic, J.; Hollenberg, Norman K.

In: Journal of Cardiovascular Pharmacology, Vol. 16, No. 2, 1990, p. 286-291.

Research output: Contribution to journalArticle

@article{5ef4bc18abb147e68ab5047d730b7fc6,
title = "Myocardial infarction treated with two lymphagogues, calcium dobesilate (CLS 2210) and hyaluronidase: A coded, placebo-controlled animal study",
abstract = "The effects on the evolution of canine myocardial infarction (MI) of the lymphagogues hyaluronidase (hyaluronate glucanohydrolase) (known to reduce the size of MIs) and calcium dobesilate (calcium, 2,5-dihydroxybenzenesulfonate, CLS 2210) were compared in a coded, placebo-controlled study in 48 dogs, during the first 24 h after coronary occlusion. Ml was induced by embolization of the anterior descending branch of the left coronary artery. The animals were given either a placebo, CLS 2210, or hyaluronidase by intravenous infusion begun immediately after embolization and continued for 24 h. The volume of myocardial tissue at risk was evaluated at 2 and 24 h by ungated computed tomography (CT), and after necropsy by staining myocardial sections with triphenyl tetrazolium chloride (TTC). Electrocardiography and estimation of serum creatine kinase (CK.) activity were also performed. In the 25 animals that survived 24 h, the results of all tests showed that there was less myocardial damage in the animals treated with the two lymphagogues than in those treated with placebo, and less damage with CLS 2210 than with hyaluronidase. The good correlation between the volume of ischemic tissue as assessed by CT in vivo and as assessed by TTC staining after necropsy (r = 0.959) confirms that the CT per-fusion phase defect accurately reflects the volume of tissue at risk during the evolution of MI. This study has shown that CLS 2210 is at least as effective as hyaluronidase in reducing myocardial damage due to coronary artery occlusion in dogs.",
keywords = "Calcium dobesilate (CLS 2210), Computed tomography, Creatine kinase, Electrocardiography, Hyaluronidase, Myocardial infarction, Triphenyl tetrazolium chloride",
author = "I. Repa and {Daniel Garnic}, J. and Hollenberg, {Norman K.}",
year = "1990",
language = "English",
volume = "16",
pages = "286--291",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Myocardial infarction treated with two lymphagogues, calcium dobesilate (CLS 2210) and hyaluronidase

T2 - A coded, placebo-controlled animal study

AU - Repa, I.

AU - Daniel Garnic, J.

AU - Hollenberg, Norman K.

PY - 1990

Y1 - 1990

N2 - The effects on the evolution of canine myocardial infarction (MI) of the lymphagogues hyaluronidase (hyaluronate glucanohydrolase) (known to reduce the size of MIs) and calcium dobesilate (calcium, 2,5-dihydroxybenzenesulfonate, CLS 2210) were compared in a coded, placebo-controlled study in 48 dogs, during the first 24 h after coronary occlusion. Ml was induced by embolization of the anterior descending branch of the left coronary artery. The animals were given either a placebo, CLS 2210, or hyaluronidase by intravenous infusion begun immediately after embolization and continued for 24 h. The volume of myocardial tissue at risk was evaluated at 2 and 24 h by ungated computed tomography (CT), and after necropsy by staining myocardial sections with triphenyl tetrazolium chloride (TTC). Electrocardiography and estimation of serum creatine kinase (CK.) activity were also performed. In the 25 animals that survived 24 h, the results of all tests showed that there was less myocardial damage in the animals treated with the two lymphagogues than in those treated with placebo, and less damage with CLS 2210 than with hyaluronidase. The good correlation between the volume of ischemic tissue as assessed by CT in vivo and as assessed by TTC staining after necropsy (r = 0.959) confirms that the CT per-fusion phase defect accurately reflects the volume of tissue at risk during the evolution of MI. This study has shown that CLS 2210 is at least as effective as hyaluronidase in reducing myocardial damage due to coronary artery occlusion in dogs.

AB - The effects on the evolution of canine myocardial infarction (MI) of the lymphagogues hyaluronidase (hyaluronate glucanohydrolase) (known to reduce the size of MIs) and calcium dobesilate (calcium, 2,5-dihydroxybenzenesulfonate, CLS 2210) were compared in a coded, placebo-controlled study in 48 dogs, during the first 24 h after coronary occlusion. Ml was induced by embolization of the anterior descending branch of the left coronary artery. The animals were given either a placebo, CLS 2210, or hyaluronidase by intravenous infusion begun immediately after embolization and continued for 24 h. The volume of myocardial tissue at risk was evaluated at 2 and 24 h by ungated computed tomography (CT), and after necropsy by staining myocardial sections with triphenyl tetrazolium chloride (TTC). Electrocardiography and estimation of serum creatine kinase (CK.) activity were also performed. In the 25 animals that survived 24 h, the results of all tests showed that there was less myocardial damage in the animals treated with the two lymphagogues than in those treated with placebo, and less damage with CLS 2210 than with hyaluronidase. The good correlation between the volume of ischemic tissue as assessed by CT in vivo and as assessed by TTC staining after necropsy (r = 0.959) confirms that the CT per-fusion phase defect accurately reflects the volume of tissue at risk during the evolution of MI. This study has shown that CLS 2210 is at least as effective as hyaluronidase in reducing myocardial damage due to coronary artery occlusion in dogs.

KW - Calcium dobesilate (CLS 2210)

KW - Computed tomography

KW - Creatine kinase

KW - Electrocardiography

KW - Hyaluronidase

KW - Myocardial infarction

KW - Triphenyl tetrazolium chloride

UR - http://www.scopus.com/inward/record.url?scp=0025314171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025314171&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 286

EP - 291

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 2

ER -